Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | SMC2 | O95347 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.47 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 5/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3870169 | 0.88 | MAP2K1 (0.51) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL18752668 | 0.85 | MAP2K1 (0.50) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL1041456 | 0.85 | MAP2K1 (0.56) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL2277841 | 0.84 | MAP2K1 (0.60) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL4546113 | 0.84 | MAP2K1 (0.61) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL18752908 | 0.84 | MAP2K1 (0.45) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL2023620 | 0.84 | MAP2K1 (0.57) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL2280384 | 0.81 | MAP2K1 (0.45) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL1040484 | 0.81 | MAP2K1 (0.43) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL18752853 | 0.81 | MAP2K1 (0.47) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3000810-B1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | ARRAY BIOPHARMA INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-3000810-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | Array Biopharma, Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2275102-B1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8513293-B2 | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal | ARRAY BIOPHARMA INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120277277-A1 | Methods of Treating a Hyperproliferative Disorder or Inhibiting Cell Growth in a Mammal | ARRAY BIOPHARMA INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8193230-B2 | Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193231-B2 | Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8178693-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110158971-A1 | COMPOSITIONS COMPRISING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100261718-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100260714-A1 | COMPOSITIONS COMPRISING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-10-14 | — | — | US | disclosed |
| EP-1482932-B1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-1663210-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2009-04-22 | — | — | EP | disclosed |
| CN-1874768-A | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2006-12-06 | — | — | CN | disclosed |
| EP-1663210-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1482932-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-05 | — | — | EP | disclosed |
| CN-1652776-A | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2005-08-10 | — | — | CN | disclosed |
| WO-2005023251-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1482932-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003077914-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261718-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CDK9, NRAS | MAP2K1 198/4885MAP2K2 168/4885EGFR 235/4885 |
| US-20120277277-A1 | Methods of Treating a Hyperproliferative Disorder or Inhibiting Cell Growth in a Mammal | PCNA, MKI67, HRAS | MAP2K1 1776/4885MAP2K2 1553/4885EGFR 273/4885 |
| US-20110158971-A1 | COMPOSITIONS COMPRISING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS AND METHODS OF USE THEREOF | NRAS, BRAF, CCNI | MAP2K1 257/4885MAP2K2 167/4885EGFR 259/4885 |
| US-20100260714-A1 | COMPOSITIONS COMPRISING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS AND METHODS OF USE THEREOF | NRAS, BRAF, ABL1 | MAP2K1 259/4885MAP2K2 171/4885EGFR 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.